News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Somaxon Pharmaceuticals, Inc. Licenses Oral Nalmefene From BioTie Therapies Inc. For The Treatment Of Impulse Control Disorders



10/19/2005 5:12:11 PM

Somaxon Pharmaceuticals, Inc. today announced that it has licensed the North American rights to oral nalmefene hydrochloride, from Biotie Therapies Corp., for the treatment of impulse control disorders. Nalmefene is a specific and selective opioid receptor antagonist. Pathways involving opioid receptors trigger addictive habits, such as pathological gambling. Opioid receptor antagonists may prevent neurochemical reward and reinforcement, leading to a reduction in craving.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES